UBXN8 and acute myeloid leukemia: These results were subsequently validated in the public database BloodSpot, which included 4 normal monocyte lines, 98 t(8;21) AML samples, 87 t(15;17) AML samples, 77 inv (16)/t(16;16) AML samples, 58 t(11q23)/MLL samples, and 87 complex aberrant karyotype AML samples, revealing a significant downregulation of UBXN8 expression in t(8;21) AML compared to the other subtypes of AML and healthy monocytes (Fig. 1c).